@thelancetneuro.bsky.social
The Lancet Neurology is the leading journal in clinical neurology. We publish articles and reviews that advocate change in, or illuminate, clinical practice.
@thelancet.comReposted by @thelancetneuro.bsky.socialICYMI - Radiotherapy after surgery halves risk of recurrence in a type of brain tumour that can often grow back, trial shows.
Find out more in The Lancet: spkl.io/633257VNLl #EANO2026 @eanoassociation.bsky.social
@thelancetneuro.bsky.socialNow online: the October 2026 issue of @lancetrh-americ.bsky.social includes papers on the burden of noncommunicable and injury-related nervous system disorders in the Americas and on the economic burden of mild traumatic brain injury in the USA www.thelancet.com/journals/lan...
@thelancet.comReposted by @thelancetneuro.bsky.socialš§ Migraine is a chronic neurological disorder that affects over 1 billion people globally each year, with women predominantly affected.
A new Seminar discusses typical symptoms, mechanisms, and treatment options: spkl.io/633257VNQH
@thelancet.comReposted by @thelancetneuro.bsky.socialš Out now: The Lancet Regional Health ā Eastern Mediterraneanās inaugural issue. #goldopenaccess
āThe scale of the challenges the region has faced this past year can be hard to absorb. It is in this context that this journal takes shape.ā
Explore the new issue: spkl.io/633277VQx7
@thelancetneuro.bsky.socialNow online @thelancet.com: a new Seminar on migraine, covering epidemiology, clinical presentation, diagnosis, and outcomes, pathophysiology, and treatment www.thelancet.com/journals/lan...
@lancetobgyn-wh.bsky.socialReposted by @thelancetneuro.bsky.socialNew Online, a Review by Connar Westgate & colleagues of idiopathic intracranial hypertension, a disorder that primarily affects young women with obesity.
Read more about this increasingly common disorder, and the implications for reproductive health and pregnancy: www.thelancet.com/journals/lan...
@lancetimaging.bsky.socialReposted by @thelancetneuro.bsky.socialšRead one of our editor picks for September
Tao et coll from TRACK-FA neuroimaging consortium evaluated the potential of geometric brain signatures for characterising hereditary ataxia and predicting functional brain organisation.
@thelancetrheum.bsky.socialReposted by @thelancetneuro.bsky.socialNEWāCAR T cells for autoimmune diseases: 2026 update of the EBMTāISCTāJACIE practice harmonisation and consensus recommendations bit.ly/4rMqjLy
#MedSky #RheumSky #NeuroSky #HaemSky
@lancetimaging.bsky.socialReposted by @thelancetneuro.bsky.socialšRead one of our editor picks for September
Gatto & coll from Mayo clinic investigated the origins of off-target tau-PET binding in frontotemporal lobar degeneration, esp the contributions of TDP-43 and annexin A11. š§
@thelancetneuro.bsky.socialOur October issue In Context section includes a historical Focal Point on electrophysiology, an Insight on third sector organisations in neuropalliative care, a book review on ancient brains in the modern world, and more!
www.thelancet.com/journals/lan...
@thelancetneuro.bsky.socialAnd our editorial explores potential implications of future advances in Alzheimer's disease diagnosis and therapy: "implementation must be based on evidence, ethics, and equity to ensure that testing is both safe and accessible for everyone who stands to benefit"
www.thelancet.com/journals/lan...
@thelancetneuro.bsky.socialWith more discussion of the potential future of biomarkers and therapy for people with Alzheimer's disease in a linked Comment article www.thelancet.com/journals/lan...
@thelancetneuro.bsky.socialWe also ask the authors of the Series papers what Alzheimerās disease diagnosis might look like in 5ā10 years, in our latest podcast: www.thelancet.com/audio-do/fut...
Apple: podcasts.apple.com/zm/podcast/t...
Amazon: music.amazon.co.uk/podcasts/986...
Spotify: open.spotify.com/show/0dY5qiz...
@thelancetneuro.bsky.socialThe third Series paper explores how clinical practice for treatment of Alzheimer's disease might evolve in the next several years, if medications are approved to treat people with biomarker evidence of disease without cognitive impairment www.thelancet.com/journals/lan...
@thelancetneuro.bsky.socialThe second Series paper covers advances in neuroimaging, providing a forward-looking perspective on how they might shape clinical practice for patients with cognitive impairment and dementia www.thelancet.com/journals/lan...
@thelancetneuro.bsky.socialThe first Series paper provides expert opinion on fluid biomarkers in Alzheimer's disease and related dementia, including current and future roles in diagnosis, prognosis, monitoring, and therapy selection www.thelancet.com/journals/lan...
@thelancetneuro.bsky.socialICYMI: a Series of three papers explores how clinical practice for Alzheimer's Disease and related disorders might evolve over the next 5ā10 years, particularly related to fluid biomarkers, neuroimaging, and clinical pathways for cognitively unimpaired individuals www.thelancet.com/journals/lan...
@thelancetneuro.bsky.socialIn our October issue correspondence section: letters on brain capital versus brain capitalism, traumatic brain injury in China, and a new era for neuroimmunology in Africa www.thelancet.com/journals/lan...
@thelancetneuro.bsky.socialWith more on blood biomarkers and lecanemab in a linked Comment article: www.thelancet.com/journals/lan...
@thelancetneuro.bsky.socialOnline first: changes in Alzheimer's disease plasma biomarkers in patients receiving lecanemab www.thelancet.com/journals/lan...
